South San Francisco, United States
TRexBio is a clinical-stage biotechnology company that is focused on developing immunoregulatory medicines. Founded in 2018 and headquartered in South San Francisco, California, the company is pioneering advances in tissue Treg biology to combat inflammatory diseases. Their commitment to decoding human tissue biology is encapsulated in their slogan: "Decoding Human Tissue Biology to Create Revolutionary Therapeutics."
Utilizing a proprietary Deep Biology platform, TRexBio aims to elucidate the behavior of tissue Tregs to discover new therapeutic targets. Its lead candidate, TRB-061, is currently in a Phase 1 clinical trial targeting atopic dermatitis. This innovative TNFR2-selective agonist seeks to balance immune responses by activating effector Tregs.
Since its inception, TRexBio has attracted significant investor interest. The company recently secured a $50.00M Late VC investment on 01 January 2026, backed by a consortium of industry leaders such as Johnson & Johnson Innovation, Polaris Partners, SV Health Investors, Affinity Asset Advisors, Alexandria Venture Investments, Avego Bioscience Capital, Delos Capital, Eli Lilly, Janus Henderson Investors, Pfizer Ventures, and Balyasny Asset Management.
